Armanda NANGMO

Dr. Armanda NANGMO

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2020 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
JFJoseph Fokam
Joseph Fokam
ANArmanda NANGMO
Armanda NANGMO
CWCarlson Wandum
Carlson Wandum
DTDesire Takou
Desire Takou
MSMaria Santoro
Maria Santoro
ANAlexis Ndjolo
Alexis Ndjolo
Background: The high rate of mortality among HIV-vertically infected adolescents might be favoured by HIV drug resistance (HIVDR) emergence, which calls for timeous actions in this underserved population. We thus sought to evaluate program quality indicators (PQIs) of HIVDR among HIV-vertically infected adolescents on antiretroviral therapy (ART). Methods: A study was conducted in the Centre region of Cameroon among adolescents (10–19 years) receiving ART in two urban (The Mother–Child Centre of the Chantal BIYA Foundation, the National Social Welfare Hospital) and three rural (Mfou District Hospital, Mbalmayo District Hospital and Nkomo Medical Center) health facilities. Following an exhaustive sampling from ART registers, patient medical files and pharmacy records, data was abstracted for seven PQIs: on-time drug pick-up; retention in care; pharmacy stock outs; dispensing practices; viral load coverage; viral suppression and adequate switch to second-line. Performance in PQIs was interpreted following the WHO-recommended thresholds (desirable, fair and/or poor); with p < 0.05 considered significant. Results: Among 967 adolescents (888 urban versus 79 rural) registered in the study sites, validated data was available for 633 (554 in urban and 79 in rural). Performance in the urban vs. rural settings was respectively: on-time drug pick-up was significantly poorer in rural (79% vs. 46%, p = 0.00000006); retention in care was fair in urban (80% vs. 72%, p = 0.17); pharmacy stock outs was significantly higher in urban settings (92% vs. 50%, p = 0.004); dispensing practices was desirable (100% vs. 100%, p = 1.000); viral load coverage was desirable only in urban sites (84% vs. 37%, p < 0.0001); viral suppression was poor (33% vs. 53%, p = 0.08); adequate switch to second-line varied (38.1% vs. 100%, p = 0.384). Conclusion: Among adolescents on ART in Cameroon, dispensing practices are appropriate, while adherence to ART program and viral load coverage are better in urban settings. However, in both urban and rural settings, pharmacy stock outs, poor viral suppression and inadequate switch to second-line among adolescents require corrective public-health actions to limit HIVDR and to improve transition towards adult care in countries sharing similar programmatic features.

12 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AZArmel Zemsi
Armel Zemsi
ICI Cham
I Cham
MDM T Diallo
M T Diallo
EYE Youm
E Youm
ANArmanda NANGMO
Armanda NANGMO
Stephen J. AllenStephen J. Allen
Stephen J. Allen
The rapid growth of clinical trials in sub-Saharan Africa (sSA) since 2010 has increased opportunities to evaluate interventions for children. However, children with common comorbidities—malnutrition, HIV infection, and sickle cell disease (SCD)—may be systematically excluded, limiting the applicability of trial findings. We quantified the extent of such exclusions and identified trial characteristics associated with exclusion. We analysed phase 2–4 interventional trials registered between 2010 and 2023 in ClinicalTrials.gov, the International Standard Randomized Controlled Trials Number, and the Pan-African Clinical Trials Registry. Eligibility criteria were reviewed and trials classified as including, excluding, probably including, or probably excluding each condition. Exclusion proportions were calculated among trials not primarily targeting these populations. Associations between exclusion and trial characteristics (phase, period, disease area, design, and intervention type) were examined. Among 1,276 trials, primary exclusion rates were 37.0% (95% CI: 34.3–39.7) for malnutrition, 41.2% (38.4–44.1) for HIV, and 35.1% (32.5–37.9) for SCD. Exclusion varied by trial phase, intervention type, and disease area. Children with these high-risk conditions remain substantially underrepresented in paediatric trials in sSA, undermining generalisability and equity. More inclusive trial designs are needed.